



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

January 2023





© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

January 2023

N = 7595



Health Authority	Male	Female	All
FRASER	1518	465	1983
INTERIOR	458	120	578
NORTHERN	150	78	228
VANCOUVER COASTAL	3327	439	3766
VANCOUVER ISLAND	830	169	999
	6283	1271	7554
		Unknown/not stated:	41
		Total:	7595

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (January 2018 - January 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (January 2018 - January 2023)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (January 2018 - January 2023)






1.5 BC-CfE Enrolment: New Antiretroviral Participants
(January 2018 - January 2023)






1.6 Percent Distribution of Active Participants by CD4 Count (January 2018 - January 2023)






1.7 Percent Distribution of Inactive Participants by CD4 Count (January 2018 - January 2023)






1.8 Active and Inactive Participants (January 2018 - January 2023)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (January 2018 - January 2023)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (January 2018 - January 2023)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(January 2018 - January 2023)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT
(January 2018 - January 2023)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(January 2018 - January 2023)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (January 2018 - January 2023)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(January 2018 - January 2023)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (January 2018 - January 2023)






**1.17 Distribution of Participants on Entry/Integrase Inhibitors
at the time of first ARV Therapy by INGREDIENT
(January 2018 - January 2023)**






1.18 Baseline CD4 for Antiretroviral First Starts (January 2018 - January 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (January 2018 - January 2023)






1.20 Cumulative Resistance Testing Results by Resistance Category (January 2018 - January 2023)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (January 2018 - January 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	31	4	0	4	1	920	3	<40	4
1988	32	5	0	5	2	315	5	<40	3
1989	30	50	1	51	21	530	48	<40	3
1990	28	52	1	53	30	545	50	<40	3
1991	28	37	3	40	15	530	37	<40	3
1992	28	54	5	59	22	610	59	<40	3
1993	27	117	13	130	77	520	125	<40	3
1994	26	69	12	81	51	460	78	<40	3
1995	26	120	18	138	70	585	127	<40	3
1996	24	309	48	357	196	550	327	<40	3
1997	22	254	31	285	159	620	251	<40	3
1998	21	179	40	219	138	560	200	<40	3
1999	21	149	39	188	120	565	174	<40	3
2000	21	117	29	146	90	600	138	<40	3
2001	21	112	24	136	75	530	122	<40	3
2002	20	117	26	143	83	550	128	<40	3
2003	19	130	26	156	91	570	141	<40	3
2004	18	141	36	177	106	585	160	<40	3
2005	17	175	40	215	127	650	194	<40	3
2006	16	164	41	205	128	600	184	<40	3
2007	15	223	41	264	161	650	241	<40	3
2008	14	271	60	331	222	640	306	<40	3
2009	13	294	61	355	229	620	331	<40	3
2010	12	252	65	317	195	680	286	<40	3
2011	11	319	71	390	252	680	357	<40	3
2012	10	258	60	318	197	720	296	<40	3
2013	9	248	67	315	196	675	280	<40	3
2014	8	273	50	323	188	720	288	<40	3
2015	7	268	41	309	193	674	285	<40	3
2016	6	241	53	294	187	690	268	<40	3
2017	6	205	31	236	154	685	212	<40	3
2018	4	186	49	235	147	680	211	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	3	222	43	265	181	700	236	<40	3
2020	3	178	53	231	161	740	204	<40	3
2021	2	195	37	232	138	600	209	<40	3
2022	1	271	55	326	237	630	301	<40	3
2023	0	30	5	35	24	475	31	<40	3
Total:		6289	1275	7564					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1249	620
APR-2022	7420	778	1755	<40	1151	620
MAY-2022	7477	763	1998	<40	1304	620
JUN-2022	7482	759	1839	<40	1199	630
JUL-2022	7495	754	1761	<40	1138	648
AUG-2022	7494	758	1990	<40	1224	620
SEP-2022	7445	771	1788	<40	1084	640
OCT-2022	7470	777	1849	<40	1159	640
NOV-2022	7508	783	1899	<40	1184	630
DEC-2022	7550	787	1607	<40	983	640
JAN-2023	7595	793	2052	<40	1275	650

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	775	334	60	<40	43	490
JUN-2022	778	317	61	<40	43	400
JUL-2022	781	297	61	<50	35	453
AUG-2022	802	278	59	78	47	560
SEP-2022	858	227	70	<40	52	440
OCT-2022	842	231	83	<40	61	500
NOV-2022	825	239	79	65	56	490
DEC-2022	790	269	57	<40	44	560
JAN-2023	747	322	62	<40	43	565

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14504
FEB-2022	7371	856	8	9	151	211	-61	14529
MAR-2022	7432	800	16	9	232	160	61	14558
APR-2022	7397	834	11	1	156	178	-35	14578
MAY-2022	7450	775	13	13	205	146	53	14602
JUN-2022	7457	778	11	15	178	170	7	14639
JUL-2022	7469	781	10	13	188	176	12	14678
AUG-2022	7470	802	15	17	169	170	1	14716
SEP-2022	7426	858	13	15	146	190	-44	14744
OCT-2022	7447	842	14	17	195	172	21	14779
NOV-2022	7488	825	9	17	211	175	41	14818
DEC-2022	7520	790	19	8	212	166	32	14845
JAN-2023	7564	747	19	10	195	142	44	14880

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	445	45	7495	8.46%	85.00%	5.94%	0.60%	100.00%
AUG-2022	643	6367	441	43	7494	8.58%	84.96%	5.88%	0.57%	100.00%
SEP-2022	663	6298	439	45	7445	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6311	439	41	7470	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6324	446	42	7508	9.27%	84.23%	5.94%	0.56%	100.00%
DEC-2022	709	6350	449	42	7550	9.39%	84.11%	5.95%	0.56%	100.00%
JAN-2023	721	6385	445	44	7595	9.49%	84.07%	5.86%	0.58%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2992 41%	4 11%	2262 31%	0 0%	18 0%	29 78%	3271 44%	3 8%	1179 16%	32 86%	4354 59%
SEP-2022	4 14%	2954 40%	3 11%	2197 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1174 16%	24 86%	4353 60%
OCT-2022	6 17%	2951 40%	4 11%	2174 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1144 16%	29 83%	4389 60%
NOV-2022	7 18%	2950 40%	5 13%	2160 29%	0 0%	15 0%	26 68%	3389 46%	6 16%	1138 15%	31 82%	4421 60%
DEC-2022	4 15%	2953 40%	3 11%	2150 29%	1 4%	16 0%	18 67%	3448 47%	5 19%	1111 15%	23 85%	4449 60%
JAN-2023	6 17%	2976 40%	1 3%	2151 29%	1 3%	16 0%	23 66%	3496 47%	8 23%	1100 15%	29 83%	4474 60%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	386 26%	1 100%	1028 70%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	368 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	355 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	996 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	341 24%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	996 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	272 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	183 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 26%	0 0%	197 19%
DEC-2022	0 0%	186 19%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	193 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	11 73%	2421 43%	2 13%	2468 44%	1 7%	347 6%	0 0%	0 0%	0 0%	24 0%	1 7%	374 7%
FEB-2022	15 71%	2443 44%	6 29%	2437 44%	0 0%	331 6%	0 0%	0 0%	0 0%	21 0%	0 0%	369 7%
MAR-2022	23 85%	2536 45%	3 11%	2460 43%	1 4%	324 6%	0 0%	0 0%	0 0%	21 0%	0 0%	370 7%
APR-2022	14 74%	2574 45%	5 26%	2436 43%	0 0%	312 5%	0 0%	0 0%	0 0%	20 0%	0 0%	366 6%
MAY-2022	17 77%	2666 46%	5 23%	2455 43%	0 0%	309 5%	0 0%	0 0%	0 0%	22 0%	0 0%	360 6%
JUN-2022	29 85%	2710 47%	5 15%	2454 42%	0 0%	300 5%	0 0%	0 0%	0 0%	22 0%	0 0%	352 6%
JUL-2022	24 69%	2745 47%	7 20%	2452 42%	3 9%	297 5%	0 0%	0 0%	0 0%	22 0%	1 3%	342 6%
AUG-2022	26 76%	2790 48%	6 18%	2453 42%	1 3%	294 5%	0 0%	0 0%	1 3%	22 0%	1 3%	340 6%
SEP-2022	19 76%	2820 48%	6 24%	2434 42%	0 0%	281 5%	0 0%	0 0%	0 0%	21 0%	0 0%	323 6%
OCT-2022	28 80%	2889 49%	6 17%	2441 41%	1 3%	280 5%	0 0%	0 0%	0 0%	22 0%	0 0%	314 5%
NOV-2022	24 73%	2922 49%	8 24%	2465 41%	1 3%	276 5%	0 0%	1 0%	0 0%	22 0%	0 0%	309 5%
DEC-2022	16 70%	2976 50%	5 22%	2468 41%	1 4%	270 4%	0 0%	1 0%	0 0%	20 0%	1 4%	308 5%
JAN-2023	23 82%	3021 50%	5 18%	2496 41%	0 0%	269 4%	0 0%	1 0%	0 0%	21 0%	0 0%	303 5%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	829	11.06	691	9.22	4611	61.53	641	8.55	648	8.65	74	0.99
SEP-2022	800	10.75	692	9.29	4576	61.46	662	8.89	641	8.61	74	0.99
OCT-2022	789	10.56	673	9.01	4621	61.86	678	9.08	636	8.51	73	0.98
NOV-2022	771	10.27	682	9.08	4644	61.85	694	9.24	645	8.59	72	0.96
DEC-2022	773	10.24	663	8.78	4687	62.08	706	9.35	650	8.61	71	0.94
JAN-2023	753	9.91	666	8.77	4738	62.38	718	9.45	648	8.53	72	0.95

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	17	0	0	1	5	10	525
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12306	3762
FEB-2022	12330	3777
MAR-2022	12359	3793
APR-2022	12388	3818
MAY-2022	12379	3807
JUN-2022	12394	3809
JUL-2022	12420	3818
AUG-2022	12441	3830
SEP-2022	12460	3839
OCT-2022	12487	3860
NOV-2022	12494	3849
DEC-2022	12472	3832
JAN-2023	12467	3820

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7595
Jan-2023

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	44	60	26
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	77	105	60	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	426	580	323	
THOMPSON/CARIBOO/ SHUSWAP	20-34	25	25	17
	35-49	61	65	43
	50+	133	208	109
Total HSDA:	219	298	169	
Total HA:		766	1043	578

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		766	1043	578

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	158	216	120
Male	608	827	458

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	578	56	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	23	12
	5 years or more	13	6
	<5 years	8	8
	Total HSDA:	44	26
KOOTENAY BOUNDARY	10 years or more	47	32
	5 years or more	15	13
	<5 years	15	15
	Total HSDA:	77	60
OKANAGAN	10 years or more	279	207
	5 years or more	79	59
	<5 years	68	57
	Total HSDA:	426	323
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	138	109
	5 years or more	45	33
	<5 years	36	27
	Total HSDA:	219	169
Total HA:		766	578

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	487	360
5 years or more	152	111
<5 years	127	107
Total HA:	766	578

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	11	20
KOOTENAY BOUNDARY	78	137	23	48
OKANAGAN	238	1070	50	350
THOMPSON/CARIBOO/SHUSWAP	150	558	36	137
Total:	517	1835	120	555

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	7
KOOTENAY BOUNDARY	12
OKANAGAN	57
THOMPSON/CARIBOO/SHUSWAP	41
Total:	117

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	37	39	29
	35-49	99	103	68
	50+	257	358	193
	Total HSDA:	400	507	297
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1141	1543	863
FRASER SOUTH	0-19	9	9	9
	20-34	102	104	73
	35-49	291	318	231
	50+	623	946	510
	Total HSDA:	1025	1377	823
Total HA:		2566	3427	1983

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	18	18	18
	20-34	261	266	185
	35-49	754	811	583
	50+	1533	2332	1197
Total HA:		2566	3427	1983

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	620	792	465
Male	1946	2635	1518

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1983	53	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	262	198
	5 years or more	72	45
	<5 years	66	54
	Total HSDA:	400	297
FRASER NORTH	10 years or more	720	516
	5 years or more	233	185
	<5 years	188	162
	Total HSDA:	1141	863
FRASER SOUTH	10 years or more	637	499
	5 years or more	218	177
	<5 years	170	147
	Total HSDA:	1025	823
Total HA:		2566	1983

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1619	1213
	5 years or more	523	407
	<5 years	424	363
Total HA:		2566	1983

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	147	534	33	64
FRASER NORTH	259	1609	39	221
FRASER SOUTH	227	1778	48	485
Total:	633	3921	120	770

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	198
FRASER NORTH	715
FRASER SOUTH	459
Total:	1372

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		351	520
RICHMOND	20-34	32	33	20
	35-49	50	51	41
	50+	117	172	97
	Total HSDA:	199	256	158
VANCOUVER	0-19	12	12	11
	20-34	447	461	300
	35-49	1235	1377	876
	50+	2975	5289	2147
	Total HSDA:	4669	7139	3334
Total HA:		5219	7915	3766

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	12
	20-34	506	521	337
	35-49	1362	1513	972
	50+	3338	5868	2445
Total HA:		5219	7915	3766

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	603	965	439
Male	4614	6948	3327
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3766	55	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	240	187
	5 years or more	53	44
	<5 years	58	43
	Total HSDA:	351	274
RICHMOND	10 years or more	120	92
	5 years or more	35	27
	<5 years	44	39
	Total HSDA:	199	158
VANCOUVER	10 years or more	*	2226
	5 years or more	*	617
	<5 years	*	491
	Never on ART	*	0
	Total HSDA:	4669	3334
Total HA:	5219	3766	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	*	2505
	5 years or more	*	688
	<5 years	*	573
	Never on ART	*	0
Total HA:		5219	3766

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	188	417	42	61
RICHMOND	45	311	9	94
VANCOUVER	677	11502	210	5418
Total:	910	12230	261	5573

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	77

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		358	519
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		126	177
SOUTH VANCOUVER ISLAND	20-34	72	78	52
	35-49	193	218	151
	50+	538	857	410
	Total HSDA:	803	1153	613
Total HA:		1287	1849	999

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1287	1849	999

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	222	321	169
Male	1065	1528	830

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	999	56	590	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	217	175
	5 years or more	79	56
	<5 years	62	53
	Total HSDA:	358	284
NORTH VANCOUVER ISLAND	10 years or more	84	69
	5 years or more	28	20
	<5 years	14	13
	Total HSDA:	126	102
SOUTH VANCOUVER ISLAND	10 years or more	488	352
	5 years or more	164	133
	<5 years	151	128
	Total HSDA:	803	613
Total HA:		1287	999

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	789	596
5 years or more	271	209
<5 years	227	194
Total HA:	1287	999

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	923	74	166
NORTH VANCOUVER ISLAND	157	279	37	67
SOUTH VANCOUVER ISLAND	221	1933	34	586
Total:	581	3135	145	819

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	112
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	130
Total:	283

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	*
	35-49	15	18	*
	50+	28	36	*
	Total HSDA:	51	62	30
NORTH WEST	20-34	*	6	*
	35-49	*	38	*
	50+	*	76	*
	Total HSDA:	72	120	54
NORTHERN INTERIOR	0-19	6	6	*
	20-34	19	19	*
	35-49	57	74	*
	50+	115	196	*
	Total HSDA:	197	295	144
Total HA:		320	477	228

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	31	33	*
	35-49	96	130	*
	50+	187	308	*
Total HA:		320	477	228

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	114	175	78
Male	206	302	150

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	228	53	580	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	30	*
	5 years or more	6	*
	<5 years	15	*
	Total HSDA:	51	30
NORTH WEST	10 years or more	50	36
	5 years or more	11	10
	<5 years	11	8
	Total HSDA:	72	54
NORTHERN INTERIOR	10 years or more	103	77
	5 years or more	61	40
	<5 years	33	27
	Total HSDA:	197	144
Total HA:		320	228

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	183	128
5 years or more	78	53
<5 years	59	47
Total HA:	320	228

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	40	60	6	8
NORTH WEST	85	172	17	35
NORTHERN INTERIOR	122	498	20	190
Total:	247	730	43	233

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	5
NORTH WEST	19
NORTHERN INTERIOR	12
Total:	36

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	31	51	*
	THOMPSON/CARIBOO/SHUSWAP	26	50	*
	Total HA:	68	121	49
FRASER	FRASER EAST	34	49	27
	FRASER NORTH	47	89	40
	FRASER SOUTH	82	118	62
	Total HA:	163	256	129
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	51	21
	RICHMOND	6	11	5
	VANCOUVER	463	909	373
	Total HA:	494	971	399
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	46	80	34
	NORTH VANCOUVER ISLAND	16	30	11
	SOUTH VANCOUVER ISLAND	49	96	38
	Total HA:	111	206	83
NORTHERN	NORTH EAST	9	13	5
	NORTH WEST	31	67	25
	NORTHERN INTERIOR	68	115	54
	Total HA:	108	195	84
Total:		944	1749	744

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	601	1124	471
Female	343	625	273

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	744	53	540	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.





Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





Monthly Report

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

